Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Relapsed myeloma reports: CAR-T, bispecific Abs & combinations

Mohamad Mohty • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies CAR-T Carfilzomib Daratumumab Dexamethasone
CANDOR CARTITUDE-1

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his overview of the latest updates for multiple myeloma (MM) in the relapsed setting from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Mohty specifically discusses CAR-T, bispecific antibodies and new combination regimens.

More from Mohamad Mohty

Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Mohamad Mohty • 7 Dec 2025
Advances in GvHD management presented at ASH 2025
5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS
3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025

Related Videos

Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
1:37
Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
Mohamad Mohty • 8 Dec 2025
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
2:35
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
Mohamad Mohty • 15 Dec 2025
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
2:53
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
Mohamad Mohty • 7 Dec 2025
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
2:15
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
Mohamad Mohty • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals